Literature DB >> 20971814

β-catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

Mona Anand1, Raymond Lai, Pascal Gelebart.   

Abstract

BACKGROUND: The role of β-catenin in cancer has been most studied in tumors of epithelial cell origin. The functional status and biological significance of this protein in anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma is unknown. DESIGN AND METHODS: ALK-positive anaplastic large cell lymphoma cell lines and patients' tumor samples were examined for status of β-catenin expression and signaling. The subcellular localization of β-catenin was assessed using immunohistochemistry, sub-cellular fractionation and confocal microscopy, while its transcriptional activity was studied using the TOPFlash/FOPFlash luciferase reporter assay. To examine the biological significance of β-catenin, short interfering RNA was used to knock-down its expression; the resulting biological effects were studied using trypan-blue exclusion and MTS assay, and the impact on its various downstream targets was assessed using quantitative real-time polymerase chain reaction and western blots.
RESULTS: β-catenin was transcriptionally active in three of three ALK-positive anaplastic large cell lymphoma cell lines, and this finding correlates with the nuclear localization of β-catenin in these cells and the neoplastic cells identified in most of the patients' tumor samples. β-catenin is biologically significant in ALK-positive anaplastic large cell lymphoma, since down-regulation of β-catenin resulted in a significant reduction in their cell growth. Down-regulation of β-catenin led to a marked reduction in both the total protein level and the activated/phosphorylated form of STAT3, another signaling protein previously shown to be important in the pathogenesis of ALK-positive anaplastic large cell lymphoma. In contrast to some of the oncogenic tyrosine kinases, modulation of nucleophosmin-anaplastic lymphoma kinase expression did not result in any detectable change in the protein level, nuclear localization or tyrosine phosphorylation of β-catenin; however, inhibition of nucleophosmin-anaplastic lymphoma kinase expression significantly down-regulated the transcriptional activity of β-catenin.
CONCLUSIONS: β-catenin signaling is constitutively active in ALK-positive anaplastic large cell lymphoma and represents a previously unknown mechanism by which the high levels of STAT3 expression and activation in these tumors are sustained. Our results suggest that the interaction between oncogenic tyrosine kinases and various cell signaling proteins may be more complex than previously believed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20971814      PMCID: PMC3031693          DOI: 10.3324/haematol.2010.027086

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  35 in total

1.  Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma.

Authors:  Qian Zhang; Puthryaveett N Raghunath; Liquan Xue; Miroslaw Majewski; David F Carpentieri; Niels Odum; Stephan Morris; Tomasz Skorski; Mariusz A Wasik
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

2.  Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway.

Authors:  R Y Bai; T Ouyang; C Miething; S W Morris; C Peschel; J Duyster
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

3.  Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death.

Authors:  Alberto Zamo; Roberto Chiarle; Roberto Piva; Jennifer Howes; Yan Fan; Marco Chilosi; David E Levy; Giorgio Inghirami
Journal:  Oncogene       Date:  2002-02-07       Impact factor: 9.867

4.  IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma.

Authors:  Jennifer Dien Bard; Pascal Gelebart; Mona Anand; Zoulika Zak; Samar A Hegazy; Hesham M Amin; Raymond Lai
Journal:  Am J Pathol       Date:  2009-07-16       Impact factor: 4.307

5.  Activation of the Wnt signaling pathway in chronic lymphocytic leukemia.

Authors:  Desheng Lu; Yandong Zhao; Rommel Tawatao; Howard B Cottam; Malini Sen; Lorenzo M Leoni; Thomas J Kipps; Maripat Corr; Dennis A Carson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

6.  Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity.

Authors:  Daniel Cussac; Catherine Greenland; Serge Roche; Ren-Yuan Bai; Justus Duyster; Stephan W Morris; Georges Delsol; Michèle Allouche; Bernard Payrastre
Journal:  Blood       Date:  2003-10-16       Impact factor: 22.113

7.  Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin.

Authors:  Eun Joo Chung; Sang-Gu Hwang; PhuongMai Nguyen; Sunmin Lee; Jung-Sik Kim; Jin Woo Kim; Pierre A Henkart; Donald P Bottaro; Lilian Soon; Paolo Bonvini; Su-Jae Lee; Judith E Karp; Ho Jung Oh; Jeffrey S Rubin; Jane B Trepel
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

8.  Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma.

Authors:  Joseph D Khoury; L Jeffrey Medeiros; George Z Rassidakis; Marwan A Yared; Panagiota Tsioli; Vasiliki Leventaki; Annette Schmitt-Graeff; Marco Herling; Hesham M Amin; Raymond Lai
Journal:  Clin Cancer Res       Date:  2003-09-01       Impact factor: 12.531

9.  Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma.

Authors:  Hesham M Amin; Timothy J McDonnell; Yupo Ma; Quan Lin; Yasushi Fujio; Keita Kunisada; Vasiliki Leventaki; Pamela Das; George Z Rassidakis; Cathy Cutler; L Jeffrey Medeiros; Raymond Lai
Journal:  Oncogene       Date:  2004-07-15       Impact factor: 9.867

10.  Illegitimate WNT signaling promotes proliferation of multiple myeloma cells.

Authors:  Patrick W B Derksen; Esther Tjin; Helen P Meijer; Melanie D Klok; Harold D MacGillavry; Marinus H J van Oers; Henk M Lokhorst; Andries C Bloem; Hans Clevers; Roel Nusse; Ronald van der Neut; Marcel Spaargaren; Steven T Pals
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-05       Impact factor: 11.205

View more
  22 in total

Review 1.  Wnt/beta-catenin signaling in glioma.

Authors:  Kailiang Zhang; Junxia Zhang; Lei Han; Peiyu Pu; Chunsheng Kang
Journal:  J Neuroimmune Pharmacol       Date:  2012-03-28       Impact factor: 4.147

2.  Unique genome-wide map of TCF4 and STAT3 targets using ChIP-seq reveals their association with new molecular subtypes of glioblastoma.

Authors:  Jun-Xia Zhang; Jing Zhang; Wei Yan; Ying-Yi Wang; Lei Han; Xiao Yue; Ning Liu; Yong-Ping You; Tao Jiang; Pei-Yu Pu; Chun-Sheng Kang
Journal:  Neuro Oncol       Date:  2013-01-07       Impact factor: 12.300

Review 3.  Molecular genetics of childhood, adolescent and young adult non-Hodgkin lymphoma.

Authors:  Rodney R Miles; Rikin K Shah; J Kimble Frazer
Journal:  Br J Haematol       Date:  2016-03-11       Impact factor: 6.998

4.  The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.

Authors:  Raymond Lai; Robert J Ingham
Journal:  Ther Adv Hematol       Date:  2013-04

5.  Wnt/β-Catenin-Promoted Macrophage Alternative Activation Contributes to Kidney Fibrosis.

Authors:  Ye Feng; Jiafa Ren; Yuan Gui; Wei Wei; Bingyan Shu; Qingmiao Lu; Xian Xue; Xiaoli Sun; Weichun He; Junwei Yang; Chunsun Dai
Journal:  J Am Soc Nephrol       Date:  2017-10-11       Impact factor: 10.121

6.  RANKL immunisation inhibits prostate cancer metastasis by modulating EMT through a RANKL-dependent pathway.

Authors:  Mineon Park; Yong Jin Cho; Bora Kim; Young Jong Ko; Yuria Jang; Yeon Hee Moon; Hoon Hyun; Wonbong Lim
Journal:  Sci Rep       Date:  2021-06-09       Impact factor: 4.379

7.  The Wnt/β-catenin pathway cross-talks with STAT3 signaling to regulate survival of retinal pigment epithelium cells.

Authors:  Miryam A Fragoso; Amit K Patel; Rei E I Nakamura; Hyun Yi; Krishna Surapaneni; Abigail S Hackam
Journal:  PLoS One       Date:  2012-10-04       Impact factor: 3.240

8.  Inhibition of β-catenin and STAT3 with a curcumin analog suppresses gastric carcinogenesis in vivo.

Authors:  Yoshihiko Uehara; Masahiro Inoue; Koji Fukuda; Hiroyuki Yamakoshi; Yoshio Hosoi; Hiroaki Kanda; Masanobu Oshima; Yoshiharu Iwabuchi; Hiroyuki Shibata
Journal:  Gastric Cancer       Date:  2014-10-18       Impact factor: 7.370

9.  Aberrant expression and biological significance of Sox2, an embryonic stem cell transcriptional factor, in ALK-positive anaplastic large cell lymphoma.

Authors:  P Gelebart; S A Hegazy; P Wang; K M Bone; M Anand; D Sharon; M Hitt; J D Pearson; R J Ingham; Y Ma; R Lai
Journal:  Blood Cancer J       Date:  2012-08-10       Impact factor: 11.037

10.  Critical analysis of the potential for targeting STAT3 in human malignancy.

Authors:  Noah D Peyser; Jennifer R Grandis
Journal:  Onco Targets Ther       Date:  2013-07-30       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.